The Economic Times daily newspaper is available online now.

    Ditch your glasses - breakthrough eye drops approved by FDA to fix your near vision instantly

    Synopsis

    Vizz, a new FDA-approved eye drop, offers adults with age related near vision loss (presbyopia) a daily, non-surgical solution. Developed by Lenz Therapeutics, it works by gently shrinking the pupil to help focus on nearby objects. Backed by clinical trials, Vizz acts within 30 minutes and lasts up to 10 hours, offering freedom from reading glasses for millions.

    Global Desk
    In a major medical breakthrough, the U.S. Food and Drug Administration has approved Vizz, a once daily eye drop that helps improve near vision without the need for reading glasses. Created by Lenz Therapeutics, Vizz is the first eye drop to use aceclidine, a compound that temporarily reduces pupil size to sharpen close up focus.

    The eye drop works by creating a mild "pinhole effect" that extends the eye’s depth of focus, improving the ability to see things up close. Vizz is fast acting, with noticeable improvement in vision within 30 minutes, and the benefits can last for up to 10 hours with just one drop a day.

    Strong clinical results with minimal side effects

    Vizz was approved after being tested in three major Phase 3 trials CLARITY 1, 2, and 3. These studies involved hundreds of participants over several weeks and months. Results showed that a majority of users gained a three-line improvement in near vision on a standard eye chart, a strong indicator of effectiveness.


    Even more reassuring, the safety profile was excellent. No serious side effects were reported. A small number of users experienced mild symptoms like eye irritation, headache, or dim vision, but these effects were temporary and resolved without treatment. Importantly, Vizz did not negatively affect distance vision, making it practical for everyday use.

    A modern alternative for aging eyes

    Vizz could be a game changer for the estimated 128 million Americans living with presbyopia. Rather than relying on glasses or surgical options, patients now have access to a non-invasive, convenient treatment they can use daily. The drops are expected to be available in the U.S. by late 2025, starting with sample distributions in doctors’ offices.

    This approval marks a turning point in eye care innovation. With its fast results, strong safety data, and ease of use, Vizz offers new hope to people who want to regain near vision clarity and reduce their dependence on corrective lenses.

    FAQs:

    Q1. What is presbyopia?
    A1. Presbyopia is a common condition where the eye’s lens loses flexibility, making it hard to focus on close-up objects. It typically starts after the age of 40.

    Q2. Why does near vision get worse with age?
    A2. As we age, the lens inside the eye becomes less flexible. This makes it harder for the eye to adjust and focus on close objects.
    Add ET Logo as a Reliable and Trusted News Source


    (You can now subscribe to our Economic Times WhatsApp channel)

    (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily International News Updates.

    ...more

    (You can now subscribe to our Economic Times WhatsApp channel)

    (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily International News Updates.

    ...more
    The Economic Times

    Stories you might be interested in